Colorectal Cancer Clinical Trials in Nashville

Showing 221-240 of 314 trials

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

NCT03811652

To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.

Non Small Cell Lung Cancer Squamous (NSCLC-Sq)Head and Neck Squamous Cell Carcinoma (HNSCC)Small Cell Lung Cancer (SCLC)+3 more

MedImmune LLC8 participantsStarted Dec 2018

Huntersville, North Carolina, United States • Nashville, Tennessee, United States • Toronto, Ontario, Canada

COMPLETEDPhase 1< 1 mile

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

NCT02574663

This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.

Pancreatic CancerColorectal CancerRectal Cancer+3 more

TG Therapeutics, Inc.66 participantsStarted Sep 2015

Nashville, Tennessee, United States

COMPLETEDPhase 3< 1 mile

A Study in Second Line Metastatic Colorectal Cancer

NCT01183780

The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.

Colorectal Cancer

Eli Lilly and Company1,072 participantsStarted Dec 2010

Sedona, Arizona, United States • Tucson, Arizona, United States • Fayetteville, Arkansas, United States +210 more locations

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

A Study in Second Line Metastatic Colorectal Cancer

Colorectal Cancer Trials in Other Cities

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer

Study of Ruxolitinib in Colorectal Cancer Patients

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis

Long-term Follow-up Study Designed to Evaluate the Relative Risk of Two Colonoscopy Schedules for Patients With Small Polyps

Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis

A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors

Sym004 in Patients With Advanced Solid Tumors

Other Conditions in Nashville